Previous close | 8.10 |
Open | 8.08 |
Bid | 8.01 x 4000 |
Ask | 8.34 x 42300 |
Day's range | 8.04 - 8.12 |
52-week range | 7.70 - 9.05 |
Volume | |
Avg. volume | 5,806,082 |
Market cap | 37.031B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 28.96 |
EPS (TTM) | 0.28 |
Earnings date | N/A |
Forward dividend & yield | 0.21 (2.63%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 9.56 |
Key Insights Using the 2 Stage Free Cash Flow to Equity, Haleon fair value estimate is UK£2.62 Haleon is estimated to...
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.